CD8A and neoplasm: In order to evaluate the impact of the combination on the T cells’ compartment, tumor-free mice were vaccinated twice at 2 weeks interval, with concomitant STINGa treatment (Figure 1A) and Z13Mad25Anaxa, a KISIMA-derived construct containing one human papilloma virus (HPV)-derived CD8 epitope (Figure S1).